GNVC News Alert Genvec Inc (GNVC) 2.04 12/25/2014 01:36:26

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Genvec Inc (GNVC) 2.04 $GNVC

Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Nov 28, 11:45AM CST

EXXI: 3.45 (-0.22), EOX: 1.33 (+0.05), VTAE: 19.20 (+0.02), SN: 9.91 (-0.71), PVA: 6.56 (-0.14), ORPN: 6.25 (-0.35), LPI: 10.61 (-0.35), SNMX: 5.95 (+0.34), UAL: 64.93 (+2.45), RDUS: 37.17 (+0.11), GNVC: 2.04 (unch), GDP: 4.93 (-0.22), SFY: 4.47 (-0.06), BORN: 1.38 (+0.02), REN: 1.13 (-0.05), SCYX: 10.49 (+0.65), VGGL: 2.89 (+0.04), CMGE: 18.11 (-0.24), SLCA: 26.62 (-0.83), OAS: 16.66 (-1.05)

GenVec beats by $0.01, misses on revenue
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 7:00AM CST

GNVC: 2.04 (unch)

GenVec Reports Third Quarter 2014 Financial Results
PR Newswire - Wed Nov 12, 6:55AM CST
GenVec, Inc. (NASDAQ: GNVC) today reported financial results for the three-month and nine-month periods ended September 30, 2014. For the three-month period ended September 30, 2014, the company reported a net loss of $1.6 million or $0.10 per share on revenues of $0.3 million as compared to a net loss of $3.0 million or $0.23 per share on revenues of $1.6 million in the same period in the prior year. For the nine-month period ended September 30, 2014, the company reported a net loss of $4.2 million or $0.27 per share on revenues of $2.5 million as compared to a net loss of $9.1 million or $0.71 per share on revenues of $3.5 million in the same period in the prior year. GenVec ended the third quarter of 2014 with $12.8 million in cash, cash equivalents, and short-term investments.
GNVC: 2.04 (unch), NVS: 93.91 (+0.66)

Preclinical Data For GenVec's RSV Vaccine Candidate Presented At The 9th RSV Symposium
PR Newswire - Tue Nov 11, 6:30AM CST
GenVec, Inc. (NASDAQ: GNVC) today announced that data exploring the immune responses generated by its vaccine candidate, GV2311, were presented at the 9th International Respiratory Syncytial Virus (RSV) Symposium being held in South Africa. These data were presented by Dr. Teresa R. Johnson, Chair of the Microbiology and Immunology Department of the Edward College of Osteopathic Medicine in Virginia. GV2311 utilizes GenVec's proprietary gorilla adenovector platform. These vectors are designed to produce superior performance in gene-based vaccines, including induction of durable high-level antibody responses as well as high-level T cell responses. They have also been shown to induce increased immune responses on repeat administration.
GNVC: 2.04 (unch)

GenVec Achieves Milestone In Hearing And Balance Collaboration
PR Newswire - Wed Nov 05, 6:15AM CST
GenVec, Inc. (NASDAQ: GNVC) today announced that the company has achieved a milestone in its collaboration with Novartis for the development of treatments for hearing and balance disorders. Novartis has dosed the first patient in a clinical study to assess the safety, tolerability, and efficacy of intra-labyrinthine (IL) CGF166 in patients with severe hearing loss. Under the terms of the collaboration agreement this triggers a $3 million milestone payment to GenVec.
GNVC: 2.04 (unch), NVS: 93.91 (+0.66)

Quinterol Mallette Appointed to GenVec Board Of Directors
PR Newswire - Fri Oct 31, 6:30AM CDT
GenVec, Inc. (NASDAQ: GNVC) today announced that the Board of Directors of GenVec, Inc. appointed Quinterol J. Mallette, M.D. as a director of the company. In addition, Dr. Mallette was appointed to the board's audit committee.
GNVC: 2.04 (unch)

Zola P. Horovitz To Retire From GenVec Board
PR Newswire - Mon Oct 20, 7:00AM CDT
GenVec, Inc. (NASDAQ: GNVC) today announced the retirement of Zola P. Horovitz, Ph.D., from its board of directors effective on October 24, 2014. Dr. Horovitz joined the GenVec board in August 2003, and served as its chairman from June 2006 to November 2013. During his tenure, he also served on the Nominating and Corporate Governance and Audit Committees of the board.
GNVC: 2.04 (unch)

GenVec Reports Second Quarter 2014 Financial Results
PR Newswire - Tue Aug 12, 6:30AM CDT
GenVec, Inc. (NASDAQ: GNVC) today reported financial results for the three-month and six-month periods ended June 30, 2014. For the three-month period ended June 30, 2014, the company reported a net loss of $1.7 million or $0.10 per share on revenues of $0.1 million as compared to a net loss of $3.1 million or $0.24 per share on revenues of $0.7 million in the same period in the prior year. For the six-month period ended June 30, 2014, the company reported a net loss of $2.6 million or $0.17 per share on revenues of $2.3 million as compared to a net loss of $6.2 million or $0.48 per share on revenues of $2.0 million in the same period in the prior year. GenVec ended the second quarter of 2014 with $14.6 million in cash, cash equivalents, and liquid investments.
GNVC: 2.04 (unch)

GenVec Achieves Third Milestone In Hearing And Balance Collaboration
PR Newswire - Thu Feb 13, 5:00AM CST
GenVec, Inc. (NASDAQ: GNVC) today announced that the company has achieved the third milestone in its collaboration with Novartis for the development of treatments for hearing and balance disorders. In January 2014, Novartis filed an Investigational New Drug (IND) application with the Food and Drug Administration (FDA) for the clinical development of CGF166, the lead product candidate under the collaboration. The IND was deemed effective on February 7, 2014 and this triggered a $2 million milestone payment to GenVec under the terms of the collaboration.
GNVC: 2.04 (unch), NVS: 93.91 (+0.66)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Charter Investigation Puts ACP Exit Claims Under Lens

Updated Category News Views 105

Charter’s ACP hangover has grown from an operating headache into a governance question. Kahn Swick & Foti said on November 20, 2026, that it has begun investigating whether Charter Communications officers or directors breached fiduciary duties or otherwise broke state or federal law. That is not a finding of wrongdoing, and investors ought to keep that distinction...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 69

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
Cottage Grove Tests Holiday Demand Across Lake Norman

Updated Category News Views 125

Flour and foot traffic make a pretty honest little scoreboard. Cottage Grove Bakery is putting itself in front of Lake Norman shoppers twice on Saturday, November 21, while also taking Thanksgiving orders and laying groundwork for 2027 workplace and school visits. This is not a public-company earnings story, and nobody should pretend a tray of scones is a quarterly...

Continue Reading
TEN Holdings Raises $1.0 Million as Dilution Looms

Updated Category News Views 73

A Small Raise With a Loud Message Nothing says “we need room to breathe” quite like selling 1,492,500 new shares for $0.67 apiece. TEN Holdings closed a roughly $1.0 million gross equity offering on November 20, 2026, and investors in NASDAQ:XHLD ought to look at this for what it is: a modest cash infusion that comes with immediate dilution. The company gets capital;...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 107

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
California Initiative Puts Missed Diagnoses in Focus

Updated Category News Views 73

When Reassurance Turns Into a Risk A clean scan can become a dangerous lullaby when symptoms refuse to leave. That is the hard, unsettling territory behind Hodes Milman’s new Missed Diagnosis Project: California, launched November 20, 2026. The statewide effort focuses on breast cancer diagnostic failures: scans read as benign when more scrutiny was warranted, referrals...

Continue Reading
S&P Global's UBS AI Conference Slot Deserves Attention

Updated Category News Views 119

Thirty Minutes Can Still Matter A half-hour fireside chat is not a quarterly earnings call, and anybody treating it like one is setting themselves up for disappointment. Still, S&P Global CEO Martina Cheung appearing at the UBS Global Technology and AI Conference on December 2 deserves a spot on the calendar for owners of NYSE:SPGI. This is a company sitting in the middle...

Continue Reading
Allooloo's 100M Calls Test Capital Markets AI Data

Updated Category News Views 160

Forty-one point nine thousand issuers is a lot of financial clutter to keep straight, and Allooloo says its machines are getting called on to do precisely that at industrial scale. The Vancouver-based company reported on November 20 that its capital-markets data products now receive 100 million AI-agent calls a month—roughly 3.4 million daily, or 39 per second. That is...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 93

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 69

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading

Top 5 Most Recently Viewed Articles

Mauna Kea Technologies Advances AI Integration in Endomicroscopy

Updated Category News Views 512

Mauna Kea Technologies and its Innovative AI Patent Mauna Kea Technologies, the proud inventor of Cellvizio®, a revolutionary platform that blends probe and needle-based confocal laser endomicroscopy (p/nCLE), has taken a significant step forward in the realm of artificial intelligence in medical diagnostic procedures. Recently, the company announced the granting of a...

Continue Reading
Hot Chili Limited Secures Approval for La Verde Expansion Drilling

Updated Category News Views 168

Hot Chili Limited's Significant Progress at La Verde Hot Chili Limited (OTCQX: HHLKF) has obtained key regulatory approval to enhance the drill coverage of its La Verde copper-gold discovery. This exciting development comes as the company aims to broaden exploration activities in an area strategically important to its operations. Understanding the La Verde Project The La...

Continue Reading
Investors on High Alert as Lithium Faces Growing Demand Challenges

Updated Category News Views 261

The Lithium Debate: Rising Tensions at COP30 At the recent climate discussions, the dialogue took an unexpected turn, raising eyebrows among investors in various clean-tech sectors. For the first time in thirty years of United Nations climate negotiations, serious concerns emerged regarding the social and environmental risks associated with lithium mining, which is...

Continue Reading
Edible Garden Expands USDA Organic Herb Line in New Markets

Updated Category News Views 71

Introducing Edible Garden's Organic Product Line Edible Garden AG Incorporated has been making headlines as a leader in controlled environment agriculture (CEA). Recently, they launched their USDA Organic herb product line at Green’s Natural Foods and The Extra Supermarket, which is a significant step in their mission to provide sustainably grown and organic produce....

Continue Reading
Growth Surge: The Value of $100 Investment in Riot Platforms

Updated Category News Views 148

Understanding the Rise of Riot Platforms Investors seeking substantial growth often look to companies like Riot Platforms (NASDAQ: RIOT), which has demonstrated impressive performance over the past five years. With a remarkable annualized return of 46.95%, Riot has outpaced the market by over 34.28%. This consistent growth contributes to a current market capitalization of...

Continue Reading